Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.06	0.01	0.01	0.03
Cash & Short-Term Investments	0.06	0.01	0.01	0.03
Cash Growth	96.43%	-	-57.14%	-
Prepaid Expenses	-	0	0	0.05
Other Current Assets	8.34	5.98	-	-
Total Current Assets	8.39	6	0.01	0.07
Property, Plant & Equipment	0.69	0.69	0.69	0.69
Total Assets	9.08	6.68	0.7	0.76
Accrued Expenses	1.33	0.04	0.9	0.17
Other Current Liabilities	0.02	-	-	0.02
Total Current Liabilities	1.36	0.04	0.9	0.2
Long-Term Debt	52.17	49.43	37.9	35.4
Total Liabilities	53.53	49.47	38.8	35.6
Common Stock	0	0	0	0
Additional Paid-In Capital	72.6	72.6	72.6	72.6
Retained Earnings	-117.05	-115.38	-110.69	-107.43
Shareholders' Equity	-44.45	-42.78	-38.09	-34.83
Total Liabilities & Equity	9.08	6.68	0.7	0.76
Total Debt	52.17	49.43	37.9	35.4
Net Cash (Debt)	-52.12	-49.42	-37.89	-35.37
Net Cash Per Share	-0.33	-0.31	-0.24	-0.22
Filing Date Shares Outstanding	160	160	160	160
Total Common Shares Outstanding	160	160	160	160
Working Capital	7.04	5.96	-0.88	-0.12
Book Value Per Share	-0.28	-0.27	-0.24	-0.22
Tangible Book Value	-44.45	-42.78	-38.09	-34.83
Tangible Book Value Per Share	-0.28	-0.27	-0.24	-0.22
Machinery	0.03	0.03	0.03	0.03
Construction In Progress	0.69	0.69	0.69	0.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.